In this episode, we discuss two agents newly approved for schizophrenia -- Rexulti (brexpiprazole) and cariprazine (Vraylar).

In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.

In this podcast, we discuss three new injectable insulin formations: Toujeo (insulin glargine U-300), Humalog U-200 (insulin lispro), and Tresiba (insulin degludec).

In this episode, we discuss PCSK9 inhibitors, a new drug class for LDL lowering, with a particular focus on alirocumab (Praluent).

In this episode, we discuss the new drug class, ARNI, recently approved for heart failure with a focus on sacubatril/valsartan (Entresto) and the PARADIGM-HF trial.

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for tacrolimus (Prograf) and lithium.

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for valproic acid (Depakote/Depakene/Depakon) and digoxin (Lanoxin).

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for warfarin (Coumadin) and phenytoin (Dilantin).

In this episode, we discuss malaria prophylaxis with atovaquone/proguanil, chloroquine, hydroxychloroquine, doxycycline, mefloquine, and primaquine.

In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years. This is part 2 of a 2 part episode.